[1]孙小慧,李志远,李静蔚,等.乳移平对乳腺癌MCF-7细胞增殖、侵袭和上皮间质转化的抑制机制研究[J].西部中医药,2023,36(10):15-19.[doi:10.12174/j.issn.2096-9600.2023.10.03]
　SUN Xiaohui,LI Zhiyuan,LI Jingwei,et al.Study on the Inhibitory Mechanism of Ruyiping on the Proliferation, Invasion and Epithelial Mesenchymal Transition of MCF-7 cells in Breast Cancer[J].Western Journal of Traditional Chinese Medicine,2023,36(10):15-19.[doi:10.12174/j.issn.2096-9600.2023.10.03]
点击复制

乳移平对乳腺癌MCF-7细胞增殖、侵袭和上皮间质转化的抑制机制研究
分享到：

《西部中医药》[ISSN:2096-9600/CN:62-1204/R]

卷:
36
期数:
2023年10期
页码:
15-19
栏目:
出版日期:
2023-10-15

文章信息/Info

Title:
Study on the Inhibitory Mechanism of Ruyiping on the Proliferation, Invasion and Epithelial Mesenchymal Transition of MCF-7 cells in Breast Cancer
作者:
孙小慧1, 李志远1,2, 李静蔚1, 刘晓菲1, 孙子渊1
1.山东中医药大学附属医院，山东 济南 250014
2.山东中医药大学中医药创新研究院，山东 济南 250355
Author(s):
SUN Xiaohui1, LI Zhiyuan1,2, LI Jingwei1, LIU Xiaofei1, SUN Ziyuan1
1.Affiliated Hospital to Shandong University of Traditional Chinese Medicine, Jinan 250014, China
2.Innovative Insitute of Chinese Medicine and Pharmacy, Shandong University of Traditional Chinese Medicine, Jinan 250355, China
关键词:
乳移平; 乳腺癌; MCF-7细胞; 增殖; 侵袭; 上皮间质转化
Keywords:
breast cancer; MCF-7 cells; proliferation; invasion; epithelial mesenchymal transition
分类号:
R737.9
DOI:
10.12174/j.issn.2096-9600.2023.10.03
文献标志码:
A
摘要:
目的研究中药复方乳移平对人乳腺癌MCF-7细胞增殖和细胞周期的影响。 方法采用药物浓度递增法培养MCF-7细胞，随机分为空白对照组、乳移平组。CCK-8法检测细胞增殖水平，平板克隆形成实验检测细胞克隆能力，细胞迁移实验检测细胞水平迁移能力，流式细胞术检测不同药物对细胞周期及凋亡的影响，Western Blot检测蛋白水平的表达，明胶酶谱测定MCF-7细胞中MMP-9（matrix metalloproteinase-9，MMP-9）的活性。 结果CCK-8法显示，与空白对照组相比，乳移平组可抑制细胞增殖（P＜0.0001）。平板克隆结果显示，与空白对照组相比，乳移平给药组细胞克隆率显著降低（P＜0.0001）。划痕实验结果表明，乳移平给药组MCF-7细胞进入空腔的能力明显低于空白对照组（P＜0.05）。侵袭实验表明，乳移平给药组同空白对照组相比，MCF-7细胞的侵袭细胞数明显减少（P＜0.05）。流式细胞术结果显示，与空白对照组相比，乳移平给药组G2期细胞数量相对较少（P＜0.05）。Western Blot结果表明，同阴性空白对照组相比，乳移平下调N-钙黏蛋白、Vimentin、Snail1和Snail2的表达，而上调E-钙黏蛋白的表达（P＜0.05）。 结论乳移平对MCF-7乳细胞生长和侵袭的抑制作用，其机制可能是通过诱导细胞周期阻滞、减少MMP9的活性和抑制上皮-间质转化（EMT）。
Abstract:
ObjectiveTo study the effects of herbal compound Ruyiping on the proliferation and cell cycle of human breast cancer MCF-7 cells. MethodsMCF-7 cells were cultured using the drug concentration increment method, randomized into blank control group and Ruyiping group. CCK-8 method was used to detect the levels of cellular proliferation, plate clone formation assay to detect cell cloning ability, cell migration assay adopted to measure the migration capacity at the cellular level, flow cytometry used to detect the influence of different medicines on cell cycle and apoptosis, Western Blot applied to detect the expressions of protein, and gelatinase spectrum to detect the activity of MMP-9 in MCF-7 cells. ResultsCCK-8 method showed that, compared with blank control group, Ruyiping group could inhibit cellular proliferation (P<0.0001). The results of plate clone formation assay demonstrated that, compared with blank control group, cell cloning rate significantly decreased in Ruyiping medication group (P<0.0001). The results of scratching test displayed that the ability of MCF-7 cells to enter the cavity was lower noticeably in Ruyiping medication group than in the blank control group (P<0.05). Invasion test indicated that the number of invading cells in MCF-7 cells reduced obviously when Ruyiping medication group was compared with blank control group (P<0.05). The results of flow cytometry showed that, compared with blank control group, the number of cells at G2 stage was relatively low in Ruyiping medication group (P<0.05). Western Blot results demonstrated that, compared with negative blank control group, Ruyiping could down regulate the expressions of N-cadherin, Vimentin, Snail1 and Snail2, while up regulate the expressions of E-cadherin (P<0.05). ConclusionRuyiping could inhibit the growth and invasion of MCF-7 cells, which may be mediated by inducing cell cycle arrest, reducing the activity of MMP-9 and inhibiting epithelial-to-mesenchymal transition (EMT).

相似文献/References:

[1]王斌,王艳杰,梁贵文,等.乳积方防治乳腺癌患者术后复发转移的临床研究*[J].西部中医药,2013,26(08):101.
　WANG Bin,WANG Yanjie,LIANG Guiwen,et al.Clinical Study on RuJiFang to Prevent Postoperative Recurrence and Metastasis of Breast Cancer[J].Western Journal of Traditional Chinese Medicine,2013,26(10):101.
[2]侯俊明,江静.疏肝解郁法联合化疗治疗乳腺癌临床疗效分析[J].西部中医药,2014,27(09):1.
[3]王丽,何丽娟,朱玉芹.循证护理对乳腺癌化疗患者自尊水平和应对方式的影响[J].西部中医药,2014,27(11):134.
[4]朱慧华.纽曼护理对乳腺癌手术患者心理健康和生活质量的影响[J].西部中医药,2014,27(12):105.
[5]张晓华,张晓岚△,梁玉荣,等.综合心理干预对乳腺癌化疗患者医学应对方式及生命质量的影响[J].西部中医药,2015,28(07):123.
[6]谷雨,华海清△.中医辨证分型与乳腺癌预后的相关性研究[J].西部中医药,2015,28(04):85.
[7]刘琛,吴黎雅,赵红佳,等.人参养荣汤干预乳腺癌新辅助化疗所致气血两虚证的临床研究[J].西部中医药,2011,24(11):3.
[8]李树建.扶正祛积汤联合CEF化疗方案治疗晚期乳腺癌40例临床研究[J].西部中医药,2013,26(09):1.
　LI Shujian.Clinical Study on FuZheng QuJiTang Combined with CEF Chemotherapy in Treating 40 Patients Suffering from Advanced Mammary Cancer[J].Western Journal of Traditional Chinese Medicine,2013,26(10):1.
[9]安妮,杨俊兰.消 疒徵祛积方联合化疗对晚期乳腺癌患者血清CEA、CA125、CA153和CA19-9含量及临床疗效的影响[J].西部中医药,2013,26(03):7.
　AN Ni,YANG Junlan.Effects of XiaoZhen QuJiFang and Chemotherapy on Clinical Efficacy and Contents of Serum CEA, CA125, CA153 and CA19-9 of Patients with Mammary Cancer at Advanced Stage[J].Western Journal of Traditional Chinese Medicine,2013,26(10):7.
[10]朱竹华,许敏菊,张汀荣,等.以家庭为中心的护理模式在完全植入式静脉输液港乳腺癌化疗患者中的应用[J].西部中医药,2016,29(03):114.
　ZHU Zhuhua,XU Minju,ZHANG Dingrong,et al.FCC Applying to Breast Cancer Patients Who Received Chemotherapy by TIVAP[J].Western Journal of Traditional Chinese Medicine,2016,29(10):114.

备注/Memo

备注/Memo:
孙小慧（1984—），女，博士学位，副主任医师。研究方向：乳腺、甲状腺良恶性疾病的中医药防治。山东省自然科学基金博士基金（ZR2017BH107）；山东省齐鲁卫生与健康杰出青年人才项目（鲁卫人字〔2020〕3号）；山东中医药大学附属医院青年创新团队项目（省中科字〔2021〕4号）；山东省中医药科技发展计划项目（2019-0160，2019-0090，M-2023026）；济南市临床医学科技创新计划（2020191570）；山东中医药大学附属医院院级课题（yjkt2020）。
更新日期/Last Update: 1900-01-01